INMED PHARMACEUTICALS INC. Proceeds, Accounts Receivable, Previously Written Off, Recovery
INMED PHARMACEUTICALS INC. (INM) reported Proceeds, Accounts Receivable, Previously Written Off, Recovery of $66.78 thousand for the 12-month period ending 2024-06-30, per its 10-K filed 2024-09-30.
Financial Statements › Cash Flow › Other Cash Flow Items
us-gaap:ProceedsAccountsReceivablePreviouslyWrittenOffRecovery · last filed 2024-09-30
- INMED PHARMACEUTICALS INC. proceeds, accounts receivable, previously written off, recovery for fiscal 2024 was $66.78K.
- INMED PHARMACEUTICALS INC. proceeds, accounts receivable, previously written off, recovery for fiscal 2023 was $0.00.
| Period end | Proceeds, Accounts Receivable, Previously Written Off, Recovery 12 month |
|---|---|
| 2024-06-30 | $66.78K 10-K · filed 2024-09-30 |
| 2023-06-30 | $0.00 10-K · filed 2024-09-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |